Trials / Terminated
TerminatedNCT03596723
KPI-121 1% Versus Prednisolone for the Treatment of Inflammation Following Cataract Surgery in Children
Safety and Efficacy of KPI-121 1% Ophthalmic Suspension Versus Prednisolone Acetate Ophthalmic Suspension 1% for the Treatment of Inflammation Following Cataract Surgery in Children 0 to 3 Years of Age
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 2 (actual)
- Sponsor
- Kala Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 3 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to assess how KPI-121 1% compares to prednisolone acetate in reducing inflammation after cataract surgery in young children. Approximately half the participants will receive KPI-121 1% eye drops and the other half will receive prednisolone acetate.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KPI-121 1% | eye drops |
| DRUG | Prednisolone acetate | eye drops |
Timeline
- Start date
- 2018-07-03
- Primary completion
- 2018-09-28
- Completion
- 2018-10-18
- First posted
- 2018-07-24
- Last updated
- 2020-10-19
- Results posted
- 2020-04-07
Locations
4 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03596723. Inclusion in this directory is not an endorsement.